Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Consun Pharmaceutical GroupCPHGF +9.09%55 Median PS Value is $1.16 as of Jul. 21, 2026, which is 7% above its 10-year median of 1.08. GuruFocus rates CPHGF with a GF Score™ of 55/100 and a GF Value™ of $1.11 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 544 Drug Manufacturers companies, Consun Pharmaceutical Group ranks worse than 84.74% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Consun Pharmaceutical Group's Median PS Value or its related term are showing as below:
CPHGF'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.57 Med: 1.08 Max: 1.78
Current: 1.55
During the past 13 years, the highest Price to Median PS Value of Consun Pharmaceutical Group was 1.78. The lowest was 0.57. And the median was 1.08.
CPHGF's Price-to-Median-PS-Value is ranked worse than 84.74% of 544
companies
in the Drug Manufacturers industry
Industry Median: 0.86
vs CPHGF: 1.55
Consun Pharmaceutical Group (OTCPK:CPHGF) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Consun Pharmaceutical Group's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
1.80
/
1.16
=
1.55
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Consun Pharmaceutical Group Median PS Value Related Terms
Consun Pharmaceutical Group Median PS Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Consun Pharmaceutical Group's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Consun Pharmaceutical Group Price-to-Median-PS-Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Consun Pharmaceutical Group's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Consun Pharmaceutical Group's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 2.0604.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Consun Pharmaceutical Group's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.563.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Consun Pharmaceutical Group (CPHGF) has a Median PS Value of $1.16 as of Jul. 21, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Consun Pharmaceutical Group and its competitors. This is near median its historical median of 1.08. Over the past decade, Consun Pharmaceutical Group's Median PS Value has ranged from 0.57 to 1.78. According to the industry distribution chart, Consun Pharmaceutical Group ranks #461 out of 544 companies in the Drug Manufacturers industry, placing it in the top 84.7%.
Is Consun Pharmaceutical Group's Median PS Value too high?
Consun Pharmaceutical Group's current Median PS Value of $1.16 is near median its 10-year median of 1.08. Over the past 10 years, this metric has ranged from a low of 0.57 to a high of 1.78. The Drug Manufacturers industry median Median PS Value is 0.86. Consun Pharmaceutical Group's value of $1.16 is 34.9% above this industry median. Based on the distribution chart, Consun Pharmaceutical Group ranks #461 out of 544 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Consun Pharmaceutical Group has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Consun Pharmaceutical Group's Median PS Value compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Consun Pharmaceutical Group ranks #461 out of 544 companies for Median PS Value. This places Consun Pharmaceutical Group in the lower half of its industry. The industry median Median PS Value is 0.86. Consun Pharmaceutical Group's value of $1.16 is 34.9% above this benchmark. Historically, Consun Pharmaceutical Group's own Median PS Value has ranged from 0.57 to 1.78 over the past decade. While the company's 10-year median is 1.08 vs. the industry median of 0.86, Consun Pharmaceutical Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Drug Manufacturers company?
The median Median PS Value among Drug Manufacturers companies is 0.86, based on 544 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Consun Pharmaceutical Group's current Median PS Value of $1.16 is 34.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Consun Pharmaceutical Group and its competitors. For the Drug Manufacturers industry, the median Median PS Value is 0.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Consun Pharmaceutical Group's current Median PS Value is $1.16, which is near median its own 10-year median of 1.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Consun Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, Consun Pharmaceutical Group (CPHGF) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.11, compared to a current price of $1.80 — trading 62.2% above its estimated fair value. The current Median PS Value is $1.16, which is near median its 10-year median of 1.08 and 34.9% above the Drug Manufacturers industry median of 0.86. Consun Pharmaceutical Group's overall GF Score™ is 55/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Consun Pharmaceutical Group (CPHGF), the current Median PS Value is $1.16 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Consun Pharmaceutical Group (CPHGF) Overvalued in 2026?
Based on GuruFocus' analysis, Consun Pharmaceutical Group stock appears to be overvalued.
The current stock price of $1.80 is trading 62.2% above its estimated GF Value™ of $1.11.
GuruFocus considers Consun Pharmaceutical Group to be Significantly Overvalued.
Key valuation signals for CPHGF:
Median PS Value: $1.16 (near median its 10-year median of 1.08)
GF Value™: $1.11 vs. price of $1.80 (62.2% above fair value)
Industry Position: 34.9% above the Drug Manufacturers median (#461 of 544)
No single metric tells the full story. See the CPHGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Consun Pharmaceutical Group Ltd is a biotechnology company with a modern pharmaceutical enterprise that integrates R&D, production, and marketing. The company has two reportable segments: the Consun pharmaceutical segment, which is the key revenue driver, and makes and sells modern Chinese medicines and medical contrast medium, and the Yulin pharmaceutical segment, which manufactures and sells traditional Chinese medicines. Company derives revenue from kidney medicines, contrast mediums, orthopedics medicines, dermatologic medicines, hepatobiliary medicines, medicines for women and children, and others.
55GF Score
Get the complete analysis for CPHGF
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CPHGF has been successfully added to your 
